Altered monocyte phenotype in HIV-1 infection tends to normalize with integrase- inhibitor-based antiretroviral therapy

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  McCausland, Marie R ^a   Juchnowski, Steven M ^b   Zidar, David A ^a,b   Kuritzkes, Daniel R ^c   Andrade, Adriana ^d   Sieg, Scott F ^a   Lederman, Michael M ^a   Funderburg, Nicholas T ^e  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD131 ANTIGEN; CD14 ANTIGEN; CD16 ANTIGEN; CD163 ANTIGEN; CD36 ANTIGEN; CD38 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CX3CR1; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HLA DR ANTIGEN; RALTEGRAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CCR2 PROTEIN, HUMAN; CHEMOKINE RECEPTOR; CX3CR1 PROTEIN, HUMAN; DRUG COMBINATION; INTEGRASE INHIBITOR; LEUKOCYTE ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CARDIOVASCULAR RISK; CELL DENSITY; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; META ANALYSIS (TOPIC); MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PILOT STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TREATMENT DURATION; BLOOD; CELL SEPARATION; CLASSIFICATION; DRUG COMBINATION; FLOW CYTOMETRY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; IMMUNOPHENOTYPING; MIDDLE AGED; PATHOLOGY; VIREMIA; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIGENS, CD; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CELL SEPARATION; DRUG COMBINATIONS; EMTRICITABINE, TENOFOVIR DISOPROXIL FUMARATE DRUG COMBINATION; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HLA-DR ANTIGENS; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MONOCYTES; RALTEGRAVIR POTASSIUM; RECEPTORS, CCR2; RECEPTORS, CHEMOKINE; VIRAL LOAD; VIREMIA;

EID: 84947204241     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0139474     Document Type: Article

References (42)

1. Funderburg NT, Zidar DA, Shive C, Lioi A, Mudd J, Musselwhite LW, et al. Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood. 2012; 120(23):4599-608. doi: 10.1182/blood-2012-05-433946
2. Westhorpe CL, Maisa A, Spelman T, Hoy JF, Dewar EM, Karapanagiotidis S, et al. Associations between surface markers on blood monocytes and carotid atherosclerosis in HIV-positive individuals. Immunology and cell biology. 2014; 92(2):133-8. Epub 2013/12/04. doi: 10.1038/icb.2013.84.
3. Wilson EM, Singh A, Hullsiek KH, Gibson D, Henry WK, Lichtenstein K, et al. Monocyte-Activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection. J Infect Dis. 2014; 210(9):1396-406. Epub 2014/05/13. doi: 10.1093/infdis/jiu275
4. Zawada AM, Rogacev KS, Rotter B, Winter P, Marell RR, Fliser D, et al. SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood. 2011; 118(12):e50-61. Epub 2011/08/02. doi: 10.1182/blood-2011-01-326827.
5. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, et al. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010; 116(16):e74-80. Epub 2010/07/16. doi: 10.1182/blood-2010-02-258558.
6. Cros J, Cagnard N, Woollard K, Patey N, Zhang SY, Senechal B, et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity. 2010; 33(3):375-86. Epub 2010/09/14. doi: 10.1016/j.immuni.2010.08.012
7. Andrade A, Rosenkranz SL, Cillo AR, Lu D, Daar ES, Jacobson JM, et al. Three Distinct Phases of HIV-1 RNA Decay in Treatment-Naive Patients Receiving Raltegravir-Based Antiretroviral Therapy: ACTG A5248. The Journal of Infectious Diseases. 2013; 208(6):884-91. doi: 10.1093/infdis/jit272
8. Funderburg NT, Andrade A, Chan ES, Rosenkranz SL, Lu D, Clagett B, et al. Dynamics of Immune Reconstitution and Activation Markers in HIV+ Treatment-Naïve Patients Treated with Raltegravir, Tenofovir Disoproxil Fumarate and Emtricitabine. PLoS ONE. 2013; 8(12):e83514. doi: 10.1371/journal.pone.0083514
9. Hanley JA, Negassa A, Edwardes MDd, Forrester JE. Statistical Analysis of Correlated Data Using Generalized Estimating Equations: An Orientation. American Journal of Epidemiology. 2003; 157 (4):364-75. doi: 10.1093/aje/kwf215
10. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Stastical Computing. Retrieved from http://www.R-project.org; 2010.
11. RStudio. RStudio: Integrated development environment for R (Version 0.98.1062). 0.98.1062 ed. Boston, MA. Retrieved September, 2014.2012.
12. Carey VJ. gee: Generalized Estimation Equation solver. R package version 4.13-18 ed. CRAN2012.
13. Weinberg A, Song LY, Wilkening C, Sevin A, Blais B, Louzao R, et al. Optimization and limitations of use of cryopreserved peripheral blood mononuclear cells for functional and phenotypic T-cell characterization. Clinical and vaccine immunology: CVI. 2009; 16(8):1176-86. Epub 2009/06/12. doi: 10.1128/cvi.00342-08
14. Meijerink M, Ulluwishewa D, Anderson RC, Wells JM. Cryopreservation of monocytes or differentiated immature DCs leads to an altered cytokine response to TLR agonists and microbial stimulation. Journal of Immunological Methods. 2011; 373(1-2):136-42. doi: http://dx.doi.org/10.1016/j.jim.2011.08.010
15. Silveira GF, Wowk PF, Machado AMB, dos Santos CND, Bordignon J. Immature Dendritic Cells Generated from Cryopreserved Human Monocytes Show Impaired Ability to Respond to LPS and to Induce Allogeneic Lymphocyte Proliferation. PLoS ONE. 2013; 8(7):e71291. doi: 10.1371/journal.pone. 0071291
16. Jiang W, Lederman MM, Salkowitz JR, Rodriguez B, Harding CV, Sieg SF. Impaired Monocyte Maturation in Response to CpG Oligodeoxynucleotide Is Related to Viral RNA Levels in Human Immunodeficiency Virus Disease and Is at Least Partially Mediated by Deficiencies in Alpha/Beta Interferon Responsiveness and Production. Journal of Virology. 2005; 79(7):4109-19. doi: 10.1128/JVI.79.7.4109-4119.2005
17. Cheadle WG. The human leukocyte antigens and their relationship to infection. American journal of surgery. 1993; 165(2A Suppl):75s-81s. Epub 1993/02/01.
18. McDevitt HO. Regulation of the immune response by the major histocompatibility system. The New England journal of medicine. 1980; 303(26):1514-7. Epub 1980/12/25. doi: 10.1056/nejm198012253032606.
19. McLeish KR, Wellhausen SR, Dean WL. Biochemical basis of HLA-DR and CR3 modulation on human peripheral blood monocytes by lipopolysaccharide. Cellular immunology. 1987; 108(1):242-8. Epub 1987/08/01.
20. Engel P, Gribben J, Freeman G, Zhou L, Nozawa Y, Abe M, et al. The B7-2 (B70) costimulatory molecule expressed by monocytes and activated B lymphocytes is the CD86 differentiation antigen1994 1994-09-01 00:00:00.1402-7 p.
21. Freeman GJ, Boussiotis VA, Anumanthan A, Bernstein GM, Ke XY, Rennert PD, et al. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity. 1995; 2(5):523-32. Epub 1995/05/01.
22. Pearson LL, Castle BE, Kehry MR. CD40-mediated signaling in monocytic cells: up-regulation of tumor necrosis factor receptor-Associated factor mRNAs and activation of mitogen-Activated protein kinase signaling pathways. International immunology. 2001; 13(3):273-83. Epub 2001/02/27..
23. Yang J, Zhang L, Yu C, Yang X-F, Wang H. Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases. Biomarker Research. 2014; 2:1-. doi: 10.1186/2050-7771-2-1
24. Mina-Osorio P, Winnicka B, O'Conor C, Grant CL, Vogel LK, Rodriguez-Pinto D, et al. CD13 is a novel mediator of monocytic/endothelial cell adhesion. Journal of leukocyte biology. 2008; 84(2):448-59. Epub 2008/05/23. doi: 10.1189/jlb.1107802
25. Fitch KV, Srinivasa S, Abbara S, Burdo TH, Williams KC, Eneh P, et al. Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women. J Infect Dis. 2013; 208(11):1737-46. Epub 2013/09/18. doi: 10.1093/infdis/jit508
26. Williams DW, Anastos K, Morgello S, Berman JW. JAM-A and ALCAM are therapeutic targets to inhibit diapedesis across the BBB of CD14+CD16+ monocytes in HIV-infected individuals. Journal of leukocyte biology. 2015; 97(2):401-12. Epub 2014/11/26. doi: 10.1189/jlb.5A0714-347R
27. Petrov V, Funderburg N, Weinberg A, Sieg S. Human β defensin-3 induces chemokines from monocytes and macrophages: diminished activity in cells from HIV-infected persons. Immunology. 2013; 140 (4):413-20. doi: 10.1111/imm.12148
28. Gascon RL, Narvaez AB, Zhang R, Kahn JO, Hecht FM, Herndier BG, et al. Increased HLA-DR expression on peripheral blood monocytes in subsets of subjects with primary HIV infection is associated with elevated CD4 T-cell apoptosis and CD4 T-cell depletion. Journal of acquired immune deficiency syndromes (1999). 2002; 30(2):146-53. Epub 2002/06/05.
29. Espinosa E, Ormsby CE, Reyes-Teran G, Asaad R, Sieg SF, Lederman MM. Dissociation of CD154 and cytokine expression patterns in CD38+ CD4+ memory T cells in chronic HIV-1 infection. Journal of acquired immune deficiency syndromes (1999). 2010; 55(4):439-45. Epub 2010/10/12. doi: 10.1097/QAI.0b013e3181ef991d
30. Olvera-Garcia G, Espinosa E, Sieg SF, Lederman MM. Cytomegalovirus-specific responses of CD38+ memory T cells are skewed towards IFN-gamma and dissociated from CD154 in HIV-1 infection. AIDS (London, England). 2014; 28(3):311-6. Epub 2014/03/07. doi: 10.1097/qad.0000000000000162
31. Zhang R, Fichtenbaum CJ, Hildeman DA, Lifson JD, Chougnet C. CD40 ligand dysregulation in HIV infection: HIV glycoprotein 120 inhibits signaling cascades upstream of CD40 ligand transcription. Journal of immunology (Baltimore, Md: 1950). 2004; 172(4):2678-86. Epub 2004/02/07.
32. Hearps AC, Maisa A, Cheng WJ, Angelovich TA, Lichtfuss GF, Palmer CS, et al. HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. AIDS (London, England). 2012; 26(7):843-53. Epub 2012/02/09. doi: 10.1097/QAD.0b013e328351f756.
33. Martin GE, Gouillou M, Hearps AC, Angelovich TA, Cheng AC, Lynch F, et al. Age-Associated changes in monocyte and innate immune activation markers occur more rapidly in HIV infected women. PLoS One. 2013; 8(1):e55279. Epub 2013/02/01. doi: 10.1371/journal.pone.0055279
34. Baker JV, Hullsiek KH, Singh A, Wilson E, Henry WK, Lichtenstein K, et al. Immunologic Predictors of Coronary Artery Calcium Progression in a Contemporary HIV Cohort. AIDS (London, England). 2014; 28(6):831-40. doi: 10.1097/QAD.0000000000000145
35. Burdo TH, Lentz MR, Autissier P, Krishnan A, Halpern E, Letendre S, et al. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J Infect Dis. 2011; 204(1):154-63. Epub 2011/06/02. doi: 10.1093/infdis/jir214
36. Krishnan S, Wilson EM, Sheikh V, Rupert A, Mendoza D, Yang J, et al. Evidence for innate immune system activation in HIV type 1-infected elite controllers. J Infect Dis. 2014; 209(6):931-9. Epub 2013/11/05. doi: 10.1093/infdis/jit581
37. Hattab S, Guihot A, Guiguet M, Fourati S, Carcelain G, Caby F, et al. Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study. BMC infectious diseases. 2014; 14:122. Epub 2014/03/05. doi: 10.1186/1471-2334-14-122
38. Hileman CO, Kinley B, Scharen-Guivel V, Melbourne K, Szwarcberg J, Robinson J, et al. Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals. J Infect Dis. 2015; 212(3):345-54. Epub 2015/01/15. doi: 10.1093/infdis/jiv004
39. Grinspoon SK, Grunfeld C, Kotler DP, Currier JS, Lundgren JD, Dube MP, et al. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation. 2008; 118(2):198-210. Epub 2008/06/21. doi: 10.1161/circulationaha.107.189622
40. Grover SA, Coupal L, Gilmore N, Mukherjee J. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy. The American journal of cardiology. 2005; 95(5):586-91. Epub 2005/02/22. doi: 10.1016/j.amjcard.2004.11.004.
41. Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008; 118(2):e29-35. Epub 2008/06/21. doi: 10.1161/circulationaha.107.189624.
42. Tseng ZH, Secemsky EA, Dowdy D, Vittinghoff E, Moyers B, Wong JK, et al. Sudden cardiac death in patients with human immunodeficiency virus infection. Journal of the American College of Cardiology. 2012; 59(21):1891-6. Epub 2012/05/19. doi: 10.1016/j.jacc.2012.02.024